Chronic kidney disease (CKD) affects more than 850 million individuals worldwide and represents a major public health challenge. Despite its high prevalence, CKD is frequently underdiagnosed due to its asymptomatic nature and slow progression. Early detection is essential to prevent irreversible kidney damage and improve clinical outcomes. Urinary albumin is one of several markers used to assess kidney function. Under normal physiological conditions, albumin is retained in the bloodstream, with only minimal amounts detectable in urine, whereas elevated albumin levels in urine indicate glomerular dysfunction, particularly in patients with diabetes or hypertension.

Immunoturbidimetric determination of albumin in urine is a key diagnostic tool by offering a robust and precise method to reliably assess glomerular filtration function, especially in the early stages of kidney impairment. The relevance of urinary albumin determination is also highlighted by the fact that the 2024 KDIGO guideline recommends albumin measurement for staging CKD.

DiaSys Albumin Urine/CSF FS is a high-performance reagent designed for the precise and accurate quantification of albumin in both urine and CSF. It enables reliable detection of microalbuminuria and low-grade albuminuria, supported by high prozone security to prevent false results. The assay is complemented with dedicated calibrators and controls and can be applied on routine clinical chemistry analyzers, ensuring robust and reproducible results in renal and neurological diagnostics.